Navigator

      Support By : Li-lab

Drugs And Genes
Negative Drug Target Genes
GENE_SYMBOL DRUG_NAME Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) Potency (nM) AC50 (nM) Datasource
ATP1A2 (3S,4S,5R,6R,7R,8R,9S,10R,13R,14S,17R)-17-[(2S,3R,4R,5S)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-3,4,6,7-tetrahydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 (3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-17-[(2S,3R,4R)-3,4-dihydroxy-6-methylheptan-2-yl]-3,4,6,7-tetrahydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 (3S,4S,5R,6R,7R,8R,9S,10R,13R,14S,17R)-3,4,6,7-tetrahydroxy-17-[(2R,4S,5S)-4-hydroxy-5,6-dimethylheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 sodium;[(3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-17-[(2S,3R,4R,5S)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-3,4,6-trihydroxy-10,13-dimethyl-15-oxo-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-7-yl] sulfate NA 128000 NA NA NA NA TTD
ATP1A2 (3S,5S,6R,7R,8R,9S,10R,13R,14R,17R)-3,6,7-trihydroxy-17-[(2R,5R)-5-[(1R)-1-hydroxyethyl]-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 (3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-17-[(2S,3R,4R,5S)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-3,4,6,7-tetrahydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 (1R,2R,5Z,12R,13S,16Z)-25-(2-hydroxypyrido[3,4-b]indol-1-yl)-11,22-diazatetracyclo[11.11.2.12,22.02,12]heptacosa-5,16,25-trien-13-ol;hydrochloride NA 150000 NA NA NA NA TTD
ATP1A2 (1R,2R,12R,13S,21Z,26S,27R)-27-(2-hydroxypyrido[3,4-b]indol-1-yl)-25-oxa-3,16-diazapentacyclo[11.11.3.112,16.01,26.02,12]octacos-21-ene NA 150000 NA NA NA NA TTD
ATP1A2 (1R,2R,4R,7S,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-28-oxa-11,22-diazahexacyclo[11.11.2.12,22.14,7.02,12.04,11]octacosa-5,16,25-trien-13-ol NA 150000 NA NA NA NA TTD
ATP1A2 (1R,2R,4R,7R,11S,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-22-aza-11-azoniahexacyclo[11.11.2.12,22.02,12.04,11.07,11]heptacosa-5,16,25-trien-13-ol;chloride NA 150000 NA NA NA NA TTD
ATP1A2 (1R,2R,12R,13S,21Z,26S,27R)-27-(2-hydroxy-3,4-dihydropyrido[3,4-b]indol-1-yl)-25-oxa-3,16-diazapentacyclo[11.11.3.112,16.01,26.02,12]octacos-21-ene NA 150000 NA NA NA NA TTD
ATP1A2 (1R,2R,5Z,12R,13S,16Z)-25-(2-hydroxy-3,4-dihydropyrido[3,4-b]indol-1-yl)-11,22-diazatetracyclo[11.11.2.12,22.02,12]heptacosa-5,16,25-trien-13-ol;hydrochloride NA 110000 NA NA NA NA TTD
ATP1A2 (1R,2R,12R,13S,21Z,26S,27R)-27-(9H-pyrido[3,4-b]indol-1-yl)-25-oxa-3,16-diazapentacyclo[11.11.3.112,16.01,26.02,12]octacos-21-ene NA 150000 NA NA NA NA TTD
ATP1A2 (1S,2R,12R,13R,16Z,25R,26S)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazatetracyclo[11.11.2.12,22.02,12]heptacos-16-ene-13,26-diol NA 120000 NA NA NA NA TTD
ATP1A2 (1R,2R,4R,5Z,7R,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-triene-7,13-diol NA 150000 NA NA NA NA TTD
ATP1A2 (3S,4S,5R,6R,7R,8R,9S,10R,13R,14R,17R)-3,4,6,7-tetrahydroxy-17-[(2R,4S)-4-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one NA 128000 NA NA NA NA TTD
ATP1A2 5-(2,2,2-Trifluoroethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole NA 316227.77 NA NA NA NA TTD
ATP1A2 5-(1,1,2,2-Tetrafluoroethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole NA 158489.32 NA NA NA NA TTD
ATP1A2 2-[(4,5-Dimethoxy-2-pyridyl)methylsulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole NA 1000000 NA NA NA NA TTD
ATP1A2 2,2-Difluoro-6-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-5H-1,3-dioxolo[4,5-f]benzimidazole NA 251188.64 NA NA NA NA TTD